George Jenkins is a senior life sciences transactions lawyer with extensive experience advising on complex, strategic commercial agreements and transactions. His practice focuses on guiding emerging and established life sciences and technology companies on structuring, negotiating, and drafting collaborations, licensing, and other strategic partnering arrangements, as well as commercial agreements for the co-development/co-promotion, manufacture, distribution, and supply of goods. George advises biotech and pharmaceutical companies across the industry, ranging from startups to global pharmaceutical companies.
A key focus of George’s practice involves utilizing his extensive cross-border experience in life sciences across Europe and the U.S. He collaborates closely with Arnold & Porter’s M&A team on strategic international deals, spinouts, product divestitures, asset transfers, and transitional agreements.
George also has experience advising on regulatory issues in the life sciences sector, including licensing and regulatory requirements, to help clients develop and bring their products to market in the EU. He understands the regulatory landscape impacting the life science industry and can assist clients in aligning their commercial arrangements and transactions within the broader regulatory framework.
During his private practice career, George has also been a member of the in-house legal teams for several clients, including at Novartis in their global headquarters in Switzerland.
Experience
- An international pharmaceutical company on its collaboration and licensing partnership with an international biotechnology company to develop rare disease gene editing programs.*
- A global healthcare company on its license and collaboration agreement with a Japanese pharmaceutical company in relation to a peptide drug conjugate collaboration for $180 million upfront cash and up to $2.71 billion in potential milestones.*
- An international biopharmaceutical company on its agreement for exclusive ex-U.S. rights to develop and commercialize an RNA-targeted medicine as a potential treatment for familial chylomicronemia syndrome.*
- A Japanese multinational healthcare company, one of the largest pharmaceutical firms in Asia, on its agreement for an exclusive option to license global rights to an active immunotherapy designed to delay or slow Alzheimer’s disease progression.*
- A global pharmaceutical company on its exclusive license agreement for global rights to a next generation oral glucagon-like peptide 1 receptor agonist for the treatment of cardiometabolic conditions and obesity.*
- A U.S. based clinical-stage biopharmaceutical company on its collaboration and licensing deal with an Italian based pharmaceutical company for European rights to commercialize a next-generation CETP inhibitor.*
- A U.S.-based global healthcare company on its $680 million acquisition of a biopharmaceutical company focused on developing innovative therapeutic approaches for cancer and other diseases. *
- A global pharmaceutical company in expanding its collaboration with a biotechnology company to develop genetic medicines for eye diseases with high unmet needs.*
- A global biopharmaceutical company on its $14 billion merger with a biopharmaceutical company focused on developing novel therapies for neuropsychiatric diseases.*
- A UK based biotechnology company on its collaboration and licensing arrangements with a global pharmaceutical company to develop a novel treatment for retinal neovascular diseases.*
*Represents experience with previous employer.
Perspectives
Credentials
Education
- M.Sc., London School of Economics and Political Science - University of London, 2010
- Legal Practice Course, BPP University Law School, 2010
- Graduate Diploma in Law, Oxford Brookes University, 2008
- B.A., University of Oxford, 2007
Admissions
- England and Wales
Activities
- ReachOut, Network Development Group
- Aspiring Solicitors